These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9157985)

  • 21. The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells.
    Yamazaki T; Sieber F
    Bone Marrow Transplant; 1997 Jan; 19(2):113-9. PubMed ID: 9116607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiation of HL-60 cells distinguishes between cytostatic and cytotoxic effects of the alkylphospholipid ET-18-OCH3.
    Civoli F; Pauig SB; Daniel LW
    Cancer Chemother Pharmacol; 1996; 38(3):269-72. PubMed ID: 8646802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones.
    Kuśnierczyk H; Chołody WM; Paradziej-Lukowicz J; Radzikowski C; Konopa J
    Arch Immunol Ther Exp (Warsz); 1994; 42(5-6):415-23. PubMed ID: 8572901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of cell division but not nuclear division by 1-O- octadecyl-2-O-methyl-Sn-glycero-3-phosphocholine.
    Pushkareva MY; Janoff AS; Mayhew E
    Cell Biol Int; 1999; 23(12):817-28. PubMed ID: 10772756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity of leukemia cell lines to cytotoxic alkyl-lysophospholipids in relation to O-alkyl cleavage enzyme activities.
    Unger C; Eibl H; Kim DJ; Fleer EA; Kötting J; Bartsch HH; Nagel GA; Pfizenmaier K
    J Natl Cancer Inst; 1987 Feb; 78(2):219-22. PubMed ID: 3468284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiinvasive activity of hexadecylphosphocholine in vitro.
    Schallier DC; Bruyneel EA; Storme GA; Hilgard P; Mareel MM
    Anticancer Res; 1991; 11(3):1285-92. PubMed ID: 1888162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes.
    Daoud SS; Juliano RL
    Cancer Res; 1986 Nov; 46(11):5518-23. PubMed ID: 3756900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity, pharmacokinetics and tissue distribution of TLC ELL-12 (liposomal antitumor ether lipid) in rats with transplantable, s.c. methylnitrosourea-induced tumors.
    Bhamra R; Bolcsak LE; Ahmad I; Schupsky J; Roberts P; Stevens R; Cavanaugh C; Swenson CE
    Anticancer Drugs; 2003 Jul; 14(6):481-6. PubMed ID: 12853892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small cell lung carcinoma exhibits greater phospholipase C-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma.
    Strassheim D; Shafer SH; Phelps SH; Williams CL
    Cancer Res; 2000 May; 60(10):2730-6. PubMed ID: 10825148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation.
    Dietzfelbinger HF; Kühn D; Zafferani M; Hanauske AR; Rastetter JW; Berdel WE
    Cancer Res; 1993 Aug; 53(16):3747-51. PubMed ID: 8339286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs.
    Andresen TL; Davidsen J; Begtrup M; Mouritsen OG; Jørgensen K
    J Med Chem; 2004 Mar; 47(7):1694-703. PubMed ID: 15027860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine.
    Boggs KP; Rock CO; Jackowski S
    J Biol Chem; 1995 May; 270(19):11612-8. PubMed ID: 7744800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The degradation of platelet-activating factor and related lipids: susceptibility to phospholipases C and D.
    Wilcox RW; Wykle RL; Schmitt JD; Daniel LW
    Lipids; 1987 Nov; 22(11):800-7. PubMed ID: 3444369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
    Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
    Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
    Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
    Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The antitumor activity of liposomal aclarubicin in vitro and in vivo].
    Viadro MM; Navashin SM
    Biull Eksp Biol Med; 1991 Nov; 112(11):523-5. PubMed ID: 1810495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.